FDA Citalopram Warning 'Without Merit'FDA Citalopram Warning 'Without Merit'

A recent FDA warning about an increased risk for cardiovascular events and mortality with higher doses of the antidepressant citalopram is "without merit," new research suggests. Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Source Type: news